CardioDynamics Announces Registration of Allen E. Paulson Trust Shares to Facilitate Private Institutional Sales.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--April 1, 2003 CardioDynamics (Nasdaq:CDIC CDIC Chronic Diseases In Canada (journal) CDIC Canadian Deposit Insurance Corporation CDIC Carbon Dioxide Information Center CDIC Center for Data Intensive Computing (BNL) ), the innovator and leader of Impedance Cardiography Impedance cardiography is a hemorheology technique of using sensors to detect the properties of the blood flow in the Thorax. Introduction Impedance cardiography (ICG), also referred to as thoracic electrical bioimpedance (TEB) and electrical impedance plethysmography (ICG ICG indocyanine green. ) technology, today announced it had filed a registration statement with the Securities and Exchange Commission covering resale of up to two million shares by the Allen E. Paulson Allen Eugene Paulson (April 22, 1922 - July 19, 2000) was an American businessman, philanthropist, thoroughbred racehorse breeder and owner, and a self-made multi-millionaire. Business career in aviation Born in Clinton, Iowa, Allen E. Trust. The company has agreed to facilitate the private sale of up to one million shares to be sold to institutional investors in privately negotiated transactions. The remaining one million shares are anticipated to be sold in privately negotiated transactions in late 2003 or early 2004, assuming appropriate market conditions. Michael K. Perry, chief executive officer of CardioDynamics, stated, "Over the last five years, the Years, The the seven decades of Eleanor Pargiter’s life. [Br. Lit.: Benét, 1109] See : Time company has assisted in reducing the Paulson Trust's beneficial ownership in the company from 78%, to less than 15%, largely through privately negotiated transactions. Once the shares covered by this registration statement have been placed, the Paulson Trust's ownership will be just over 10%." Perry continued, "In the latter half of 2001, the company assisted in the placement of 4.2 million shares owned by the Paulson Trust and Scripps Research Foundation to institutional investors in private transactions without impacting the market for the company's stock. We remain committed to avoiding undue impact on the orderly market Orderly Market Any market in which the supply and demand are reasonably equal. Notes: Orderly markets usually don't have volatile price swings and prices are competitive, reflecting the true value of the good or service. for our stock through these efforts." Perry concluded, "This is part of an ongoing process to diversify ownership of the company and further increase our institutional holdings. We are pleased to assist the Paulson Trust in meeting its financial needs and also to fulfill the interest of investors that are increasingly recognizing the company's progress, market potential and contributions to healthcare." About CardioDynamics CardioDynamics, the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG). The company's BioZ(R) Systems are being used by leading physicians around the world to help battle the number one killer of men and women -- cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . Partners include GE Medical Systems Information Technologies, Philips Medical Systems, and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, refer to the company's Web site at www.cdic.com. Forward-Looking (Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. ) Statement Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, such as estimated ICG industry market size and prospects, company growth and penetration rates, the accuracy of which is necessarily subject to uncertainties and risks including the company's sole dependence on the BioZ product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the company's filings with the SEC, including its 2002 Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . The company does not undertake to update the disclosures contained in this press release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion